One-Time CAR-T Infusion Prevents Myeloma Progression in 100% of Trial Patients
A single CAR-T cell infusion drove complete remission in all 20 high-risk smoldering myeloma patients, raising hopes of a one-and-done cure.
Summary
A small but striking phase II trial called CAR-PRISM found that a single infusion of the CAR-T therapy cilta-cel (Carvykti) produced deep, lasting remissions in all 20 patients with high-risk smoldering multiple myeloma — a precursor condition that carries roughly a 50% chance of progressing to active myeloma within two years. Every patient achieved the lowest measurable level of minimal residual disease negativity within two months, and 90% had a complete or stringent complete response. Results were sustained over a median 15-month follow-up. Presented at the AACR annual meeting and published in Nature Medicine, these findings suggest that intervening early — before the immune system is compromised by active disease — may dramatically improve outcomes and potentially prevent myeloma from ever developing.
Detailed Summary
Multiple myeloma is a blood cancer that causes serious organ damage and remains largely incurable in its active form. Before it becomes active, many patients pass through a stage called smoldering multiple myeloma, where cancer cells are present but not yet causing symptoms. High-risk smoldering myeloma carries roughly a 50% chance of progressing to active disease within two years, yet until recently, the standard approach was simply to watch and wait.
The CAR-PRISM trial tested whether intervening at this early stage with a single infusion of cilta-cel — a CAR-T cell therapy that targets a protein called BCMA on myeloma cells — could stop the disease before it causes harm. All 20 enrolled patients achieved minimal residual disease negativity at the most sensitive measurable level within two months of treatment. Ninety percent achieved a complete or stringent complete response, and these results held in patients followed beyond 18 months.
Researchers from Dana-Farber Cancer Institute believe the early intervention window is key. At the smoldering stage, tumor burden is lower and the immune system is less damaged, potentially allowing CAR-T cells to work more effectively. This is a fundamentally different strategy from current practice, where treatment typically begins only after active disease causes symptoms — by which point irreversible organ damage may already have occurred.
Experts at the AACR meeting called the efficacy data phenomenal, with one discussant raising the possibility of using the word cure for selected patients. However, several participants experienced a neurological side effect called non-immune effector cell-associated neurotoxicity syndrome, with some reporting mild but persistent motor symptoms, tempering the otherwise exceptional results.
This trial is small and early-phase, so larger confirmatory studies are needed before cilta-cel could be approved for smoldering myeloma. Still, for the longevity-minded, this research illustrates how early disease interception — catching and eliminating cancer before it becomes symptomatic — may represent the future of cancer prevention and healthspan extension.
Key Findings
- All 20 high-risk smoldering myeloma patients achieved deepest-level MRD negativity after a single cilta-cel infusion.
- 90% of patients had a complete or stringent complete response sustained over a median 15-month follow-up.
- Early intervention before immune compromise may allow CAR-T therapy to work more effectively than in active disease.
- No high-grade cytokine release syndrome occurred, but some patients developed mild persistent motor neurological symptoms.
- Researchers raised the possibility of a one-and-done cure for selected high-risk smoldering myeloma patients.
Methodology
This is a meeting coverage news report from MedPage Today summarizing phase II trial data presented at the AACR 2026 annual meeting and simultaneously published in Nature Medicine, a high-credibility peer-reviewed journal. The trial (CAR-PRISM) enrolled 20 patients, making it small but rigorously reported with objective MRD endpoints.
Study Limitations
The trial enrolled only 20 patients with a median follow-up of approximately 15 months, so long-term durability and safety data remain incomplete. Neurological side effects including persistent motor symptoms require further characterization before widespread adoption. Larger randomized trials are needed to confirm efficacy and establish whether this approach is superior to current approved therapies like daratumumab.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.